日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting human plasma cells using regulated BCMA CAR T cells eliminates circulating antibodies in humanized mice.

利用调控的BCMA CAR T细胞靶向人类浆细胞,可消除人源化小鼠体内的循环抗体

Honaker Yuchi, Gruber David, Jacobs Chester, Yu-Hong Cheng Rene, Patel Shivani, Galvan Christopher Zavala, Khan Iram F, Zhou Kevin, Sommer Karen, Astrakhan Alexander, Cook Peter J, James Richard G, Rawlings David J

Transcriptional fingerprinting of regulatory T cells: ensuring quality in cell therapy applications

调节性T细胞的转录指纹图谱:确保细胞治疗应用的质量

Cheng, Zhang; Wang, Li-Jie; Honaker, Yuchi; Cincotta, Steven A; Page, Claire E; Vollhardt, Sydney; Yuan, Victor; Long, S Alice; Xiao, Yuanyuan; Beilke, Joshua N; Arron, Joseph R; Bluestone, Jeffrey A

HLA-A2 CAR/IL-2-CISC engineered Treg display robust in vitro and in vivo antigen-specific regulatory function

HLA-A2 CAR/IL-2-CISC工程化Treg细胞在体外和体内均表现出强大的抗原特异性调节功能。

Tripathi, Subhash K; Grimm, Annaiz; Dahl, Noelle P; Honaker, Yuchi; Knebusch, Parker; Chen, Yu; Cook, Peter J; Rawlings, David J

αE-catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway

αE-catenin抑制Src-YAP1致癌模块,该模块连接酪氨酸激酶和Hippo信号通路效应因子。

Li, Peng; Silvis, Mark R; Honaker, Yuchi; Lien, Wen-Hui; Arron, Sarah T; Vasioukhin, Valeri

GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers.

GSK-3β 靶向 Cdc25A 进行泛素介导的蛋白水解,GSK-3β 失活与人类癌症中 Cdc25A 的过度产生相关

Kang Tiebang, Wei Yongkun, Honaker Yuchi, Yamaguchi Hiroshi, Appella Ettore, Hung Mien-Chie, Piwnica-Worms Helen